These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29431311)

  • 21. Anti-tumor activities of 1-Acetyl-3-o-Toluyl-5-Fu.
    Okada T
    Hiroshima J Med Sci; 1979 Mar; 28(1):49-66. PubMed ID: 457437
    [No Abstract]   [Full Text] [Related]  

  • 22. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
    Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
    Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.
    De Wolf K; Rottey S; Vermaelen K; Decaestecker K; Sundahl N; De Lobel L; Goetghebeur E; De Meerleer G; Lumen N; Fonteyne V; De Maeseneer D; Ost P
    Radiat Oncol; 2017 Sep; 12(1):157. PubMed ID: 28938918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
    Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
    Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J
    Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 27. Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma.
    Shiozawa K; Shuting J; Yoshioka Y; Ochiya T; Kondo T
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1322-1327. PubMed ID: 29191657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
    Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
    Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
    Katz D; Azraq Y; Eleyan F; Gill S; Peretz T; Merimsky O
    BMC Cancer; 2016 Aug; 16():616. PubMed ID: 27501793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
    Verbiest A; Couchy G; Job S; Zucman-Rossi J; Caruana L; Lerut E; Oyen R; de Reyniès A; Laguerre B; Rioux-Leclercq N; Wozniak A; Joniau S; Van Poppel H; Van Den Eynde K; Beuselinck B
    Clin Genitourin Cancer; 2018 Jun; 16(3):e605-e612. PubMed ID: 29239846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary leiomyosarcoma metastatic to the thyroid gland: case report and review of the literature.
    Woo Young K; Young Ran K; Sang Uk W; Jae Bok L
    Ann Endocrinol (Paris); 2011 Sep; 72(4):314-316. PubMed ID: 21784409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
    Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G
    Urol Oncol; 2017 Sep; 35(9):541.e7-541.e13. PubMed ID: 28572027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
    Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
    Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
    Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized
    Ravoori MK; Singh SP; Lee J; Bankson JA; Kundra V
    Radiology; 2017 Dec; 285(3):830-838. PubMed ID: 28707963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Targeting mTOR and identification of « exceptional responders »].
    Robert J
    Bull Cancer; 2014 Sep; 101(9):775. PubMed ID: 25295532
    [No Abstract]   [Full Text] [Related]  

  • 40. Metastatic uterine leiomyosarcoma coexisting with papillary carcinoma of the thyroid gland.
    Giannikaki E; Mantadakis E; Mamalaki E; Delides G; Samonis G
    Int J Gynecol Cancer; 2006; 16(1):442-5. PubMed ID: 16445675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.